Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Fig. 2

Kaplan-Meier survival curves for PFS (A, C, and E) and OS (B, D, and F) among patients stratified according to prognostic factors: starting dose of afatinib (A and B), liver metastases (C and D), and clinical tumor responses (E and F). PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease, PD progressive disease; NA, not assessed

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us